BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012;1:144-58. [PMID: 24159579 DOI: 10.1159/000343828] [Cited by in Crossref: 169] [Cited by in F6Publishing: 173] [Article Influence: 21.1] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Xu Y, Ma W, Wu H, Xu G, Chekhonin VP, Peltzer K, Wang X, Wang G, Zhang C. The homogeneity and heterogeneity of occurrence, characteristics, and prognosis in hepatocellular carcinoma patients with synchronous and metachronous bone metastasis. J Cancer 2022;13:393-400. [PMID: 35069889 DOI: 10.7150/jca.65308] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Jiang L, Lei JY, Wang WT, Yan LN, Li B, Wen TF, Xu MQ, Yang JY, Wei YG. Immediate Radical Therapy or Conservative Treatments When Meeting the Milan Criteria for Advanced HCC Patients After Successful TACE. J Gastrointest Surg 2014;18:1125-30. [DOI: 10.1007/s11605-014-2508-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
3 Glantzounis GK, Tokidis E, Basourakos SP, Ntzani EE, Lianos GD, Pentheroudakis G. The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review. Eur J Surg Oncol. 2017;43:32-41. [PMID: 27283892 DOI: 10.1016/j.ejso.2016.05.026] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 8.2] [Reference Citation Analysis]
4 Geng S, Pan T, Zhou W, Cui H, Wu L, Li Z, Chu PK, Yu XF. Bioactive phospho-therapy with black phosphorus for in vivo tumor suppression. Theranostics 2020;10:4720-36. [PMID: 32308745 DOI: 10.7150/thno.43092] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
5 Xiao Z, Ching Chow S, Han Li C, Chun Tang S, Tsui SK, Lin Z, Chen Y. Role of microRNA-95 in the anticancer activity of Brucein D in hepatocellular carcinoma. Eur J Pharmacol 2014;728:141-50. [PMID: 24530415 DOI: 10.1016/j.ejphar.2014.02.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
6 Ma H, Jiang C. Dehydroascorbic Acid and pGPMA Dual Modified pH-Sensitive Polymeric Micelles for Target Treatment of Liver Cancer. J Pharm Sci 2018;107:595-603. [PMID: 29024701 DOI: 10.1016/j.xphs.2017.09.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
7 Chuncharunee A, Siramolpiwat S. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment. Asian Pac J Cancer Prev 2017;18:1697-701. [PMID: 28670891 DOI: 10.22034/APJCP.2017.18.6.1697] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
8 Lin HS, Wan RH, Gao LH, Li JF, Shan RF, Shi J. Adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma: a systematic review and a meta-analysis. Hepatobiliary Pancreat Dis Int. 2015;14:236-245. [PMID: 26063023 DOI: 10.1016/s1499-3872(15)60373-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
9 Panera N, Crudele A, Romito I, Gnani D, Alisi A. Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma. Int J Mol Sci 2017;18:E99. [PMID: 28067792 DOI: 10.3390/ijms18010099] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
10 Hu HT, Shan QY, Chen SL, Li B, Feng ST, Xu EJ, Li X, Long JY, Xie XY, Lu MD, Kuang M, Shen JX, Wang W. CT-based radiomics for preoperative prediction of early recurrent hepatocellular carcinoma: technical reproducibility of acquisition and scanners.Radiol Med. 2020;125:697-705. [PMID: 32200455 DOI: 10.1007/s11547-020-01174-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
11 Qu Z, Yuan CH, Yin CQ, Guan Q, Chen H, Wang FB. Meta-analysis of the prognostic value of abnormally expressed lncRNAs in hepatocellular carcinoma. Onco Targets Ther. 2016;9:5143-5152. [PMID: 27574455 DOI: 10.2147/ott] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Chen BW, Chen W, Liang H, Liu H, Liang C, Zhi X, Hu LQ, Yu XZ, Wei T, Ma T, Xue F, Zheng L, Zhao B, Feng XH, Bai XL, Liang TB. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells. Mol Cancer Ther 2015;14:1805-15. [PMID: 26026051 DOI: 10.1158/1535-7163.MCT-15-0029] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
13 Al-Dali AM, Weiher H, Schmidt-Wolf IGH. Utilizing ethacrynic acid and ciclopirox olamine in liver cancer. Oncol Lett 2018;16:6854-60. [PMID: 30405829 DOI: 10.3892/ol.2018.9472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
14 Byrne JD, Yeh JJ, DeSimone JM. Use of iontophoresis for the treatment of cancer. J Control Release 2018;284:144-51. [PMID: 29908892 DOI: 10.1016/j.jconrel.2018.06.020] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
15 Aggarwal V, Tuli HS, Thakral F, Singhal P, Aggarwal D, Srivastava S, Pandey A, Sak K, Varol M, Khan MA, Sethi G. Molecular mechanisms of action of hesperidin in cancer: Recent trends and advancements. Exp Biol Med (Maywood) 2020;245:486-97. [PMID: 32050794 DOI: 10.1177/1535370220903671] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 14.0] [Reference Citation Analysis]
16 Lurje I, Hammerich L, Tacke F. Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer. Int J Mol Sci 2020;21:E7378. [PMID: 33036244 DOI: 10.3390/ijms21197378] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
17 Hartenbach M, Weber S, Pilz M, Hartenbach S, Zacherl MJ, Paprottka PM, Tiling R, Bartenstein P, Hacker M, Haug AR, Albert NL. Combined [18F]-Fluoroethylcholine PET/CT and 99mTc-Macroaggregated Albumin SPECT/CT Predict Survival in Patients With Intermediate-Stage Hepatocellular Carcinoma. Clin Nucl Med 2018;43:477-81. [PMID: 29659390 DOI: 10.1097/RLU.0000000000002092] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Feng JK, Sun JX, Liu ZH, Gu JW, Chen ZH, Liu C, Guo WX, Shi J, Cheng SQ. Efficacy and Safety of Transarterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma Associated with Bile Duct Tumor Thrombus: A Real-World Retrospective Cohort Study. Cancer Manag Res 2021;13:3551-60. [PMID: 33953609 DOI: 10.2147/CMAR.S307065] [Reference Citation Analysis]
19 Chatterjee S, Patra D, Chakraborti U, Sengupta D, Ghosh P, Basu A, Sadhukhan GC, Chowdhury KD. Association of p38MAPK‐p53‐Fas aggregation in S‐allyl cysteine mediated regulation of hepatocarcinoma. Environmental Toxicology 2019;34:928-40. [DOI: 10.1002/tox.22764] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
20 Feng B, Zhu Y, Su Z, Tang L, Sun C, Li C, Zheng G. Basil polysaccharide attenuates hepatocellular carcinoma metastasis in rat by suppressing H3K9me2 histone methylation under hepatic artery ligation-induced hypoxia. Int J Biol Macromol 2018;107:2171-9. [PMID: 29042275 DOI: 10.1016/j.ijbiomac.2017.10.088] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
21 Babaei M, Abnous K, Taghdisi SM, Amel Farzad S, Peivandi MT, Ramezani M, Alibolandi M. Synthesis of theranostic epithelial cell adhesion molecule targeted mesoporous silica nanoparticle with gold gatekeeper for hepatocellular carcinoma. Nanomedicine (Lond). 2017;12:1261-1279. [PMID: 28520529 DOI: 10.2217/nnm-2017-0028] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
22 Chiu CC, Lee KT, Wang JJ, Sun DP, Lee HH, Shi HY. Health-Related Quality of Life before and after Surgical Resection of Hepatocellular Carcinoma: A Prospective Study. Asian Pac J Cancer Prev 2018;19:65-72. [PMID: 29373894 DOI: 10.22034/APJCP.2018.19.1.65] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
23 Chen P, Hu T, Liang Y, Jiang Y, Pan Y, Li C, Zhang P, Wei D, Li P, Jeong LS, Chu Y, Qi H, Yang M, Hoffman RM, Dong Z, Jia L. Synergistic inhibition of autophagy and neddylation pathways as a novel therapeutic approach for targeting liver cancer. Oncotarget 2015;6:9002-17. [PMID: 25797246 DOI: 10.18632/oncotarget.3282] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
24 Shetty K, He AR. A STORM in a teacup?-the challenges of adjuvant therapy in hepatocellular carcinoma (HCC). Transl Gastroenterol Hepatol 2016;1:2. [PMID: 28138570 DOI: 10.21037/tgh.2016.03.10] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Girardi DM, Pacífico JPM, Guedes de Amorim FPL, Dos Santos Fernandes G, Teixeira MC, Pereira AAL. Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives. Pharmaceuticals (Basel) 2020;14:28. [PMID: 33396181 DOI: 10.3390/ph14010028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
26 Qi F, Zhou S, Li L, Wei L, Shen A, Liu L, Wang Y, Peng J. Pien Tze Huang inhibits the growth of hepatocellular carcinoma cells by upregulating miR-16 expression. Oncol Lett 2017;14:8132-7. [PMID: 29344256 DOI: 10.3892/ol.2017.7240] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
27 Lee YH, Tai D, Yip C, Choo SP, Chew V. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond. Front Immunol 2020;11:568759. [PMID: 33117354 DOI: 10.3389/fimmu.2020.568759] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
28 Schemmer P, Burra P, Hu RH, Hüber CM, Loinaz C, Machida K, Vogel A, Samuel D. State of the art treatment of hepatitis B virus hepatocellular carcinoma and the role of hepatitis B surface antigen post-liver transplantation and resection. Liver Int 2021. [PMID: 34846790 DOI: 10.1111/liv.15124] [Reference Citation Analysis]
29 Vasuri F, Fittipaldi S, De Pace V, Gramantieri L, Bertuzzo V, Cescon M, Pinna AD, Fiorentino M, D'Errico A, Ravaioli M. Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas. Oncotarget 2018;9:17895-905. [PMID: 29707155 DOI: 10.18632/oncotarget.24860] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
30 Asai A, Yasuoka H, Matsui M, Tsuchimoto Y, Fukunishi S, Higuchi K. Programmed Death 1 Ligand Expression in the Monocytes of Patients with Hepatocellular Carcinoma Depends on Tumor Progression. Cancers (Basel) 2020;12:E2286. [PMID: 32824016 DOI: 10.3390/cancers12082286] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Landerer S, Kalthoff S, Paulusch S, Strassburg CP. UDP-glucuronosyltransferase polymorphisms affect diethylnitrosamine-induced carcinogenesis in humanized transgenic mice. Cancer Sci 2020;111:4266-75. [PMID: 32860300 DOI: 10.1111/cas.14635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
32 Korga A, Ostrowska M, Jozefczyk A, Iwan M, Wojcik R, Zgorka G, Herbet M, Vilarrubla GG, Dudka J. Apigenin and hesperidin augment the toxic effect of doxorubicin against HepG2 cells. BMC Pharmacol Toxicol 2019;20:22. [PMID: 31053173 DOI: 10.1186/s40360-019-0301-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
33 Jeong KY, Lee EJ, Yang SH, Seong J. Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma. J Radiat Res 2015;56:37-45. [PMID: 25225286 DOI: 10.1093/jrr/rru077] [Reference Citation Analysis]
34 Zhuang L, Wang X, Wang Z, Ma X, Han B, Zou H, Wu Z, Dong S, Qu Z, Zang Y, Wu L. MicroRNA-23b functions as an oncogene and activates AKT/GSK3β/β-catenin signaling by targeting ST7L in hepatocellular carcinoma. Cell Death Dis 2017;8:e2804. [PMID: 28518144 DOI: 10.1038/cddis.2017.216] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
35 Panebianco C, Saracino C, Pazienza V. Epithelial-mesenchymal transition: molecular pathways of hepatitis viruses-induced hepatocellular carcinoma progression. Tumour Biol 2014;35:7307-15. [PMID: 24833096 DOI: 10.1007/s13277-014-2075-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
36 Liao Y, Liang X, Liang W, Li Z, Wang Y, Wang L, Zhen S, Tang B, Wang Z. High expression of ubiquitin carboxyl-terminal hydrolase 22 is associated with poor prognosis in hepatitis B virus-associated liver cancer. Oncol Lett 2019;17:5159-68. [PMID: 31186731 DOI: 10.3892/ol.2019.10154] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Shi X, He D, Tang G, Tang Q, Xiong R, Ouyang H, Yu C. Fabrication and characterization of a folic acid-bound 5-fluorouracil loaded quantum dot system for hepatocellular carcinoma targeted therapy. RSC Adv 2018;8:19868-78. [DOI: 10.1039/c8ra01025k] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
38 Ma X, Jin Y, Wang Y, Zhang S, Peng D, Yang X, Wei S, Chai W, Li X, Tian J. Multimodality Molecular Imaging-Guided Tumor Border Delineation and Photothermal Therapy Analysis Based on Graphene Oxide-Conjugated Gold Nanoparticles Chelated with Gd. Contrast Media Mol Imaging 2018;2018:9321862. [PMID: 29853812 DOI: 10.1155/2018/9321862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
39 Zuo C, Xia M, Wu Q, Zhu H, Liu J, Liu C. Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review). Oncol Lett 2015;9:527-34. [PMID: 25624883 DOI: 10.3892/ol.2014.2727] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
40 Görtz M, Galli U, Longerich T, Zöller M, Erb U, Schemmer P. De novo synthesis of C4.4A in hepatocellular carcinoma promotes migration and invasion of tumor cells. Oncol Rep 2017;38:2697-704. [PMID: 29048672 DOI: 10.3892/or.2017.5980] [Reference Citation Analysis]
41 Al-Shun SA, El-Senduny FF, Ismail MA, El-Sayed WM, Badria FA, Youssef MM. Anticancer activity of new cationic arylthiophenes against hepatocellular carcinoma. Life Sci 2021;269:119028. [PMID: 33444618 DOI: 10.1016/j.lfs.2021.119028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Hu DG, Rogers A, Mackenzie PI. Epirubicin upregulates UDP glucuronosyltransferase 2B7 expression in liver cancer cells via the p53 pathway. Mol Pharmacol 2014;85:887-97. [PMID: 24682467 DOI: 10.1124/mol.114.091603] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
43 Peng Y, Liu F, Xu H, Lan X, Wei Y, Li B. Outcomes of Laparoscopic Liver Resection for Patients with Multiple Hepatocellular Carcinomas Meeting the Milan Criteria: A Propensity Score-Matched Analysis. J Laparoendosc Adv Surg Tech A 2019;29:1144-51. [PMID: 31411541 DOI: 10.1089/lap.2019.0362] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
44 Song MS, Grabocka E. Stress Granules in Cancer. Rev Physiol Biochem Pharmacol 2020. [PMID: 32789791 DOI: 10.1007/112_2020_37] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
45 Sun Q, Zhang X, Gong X, Hu Z, Zhang Q, He W, Chang X, Hu Z, Chen Y. Survival analysis between laparoscopic and open hepatectomy for hepatocellular carcinoma: a meta-analysis based on reconstructed time-to-event data. Hepatol Int 2021. [PMID: 34258665 DOI: 10.1007/s12072-021-10219-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Qu Z, Yuan CH, Yin CQ, Guan Q, Chen H, Wang FB. Meta-analysis of the prognostic value of abnormally expressed lncRNAs in hepatocellular carcinoma. Onco Targets Ther 2016;9:5143-52. [PMID: 27574455 DOI: 10.2147/OTT.S108599] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
47 Minami Y, Nishida N, Kudo M. Therapeutic response assessment of RFA for HCC: Contrast-enhanced US, CT and MRI. World J Gastroenterol 2014; 20(15): 4160-4166 [PMID: 24764654 DOI: 10.3748/wjg.v20.i15.4160] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
48 Ho JC, Hsieh ML, Chuang PH, Hsieh VC. Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Value Health Reg Issues 2018;15:120-6. [PMID: 29704658 DOI: 10.1016/j.vhri.2017.12.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
49 Nomura A, Ishigami M, Honda T, Kuzuya T, Ishizu Y, Ito T, Kamei H, Onishi Y, Ogura Y, Fujishiro M. Limitation of non-transplant treatment and proper timing for liver transplantation in patients with hepatocellular carcinoma considering long-term survival. Medicine (Baltimore) 2020;99:e21161. [PMID: 32664152 DOI: 10.1097/MD.0000000000021161] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Jiang X, Xu Y, Chen D, Wang M, Qiu M, Xiong L, Zhang L, Yu H, Xiong Z. A Novel Angiogenesis-Related Prognostic Signature Associated with the Hepatocellular Carcinoma Immune Microenvironment and Survival Outcome. Int J Gen Med 2022;15:311-23. [PMID: 35027841 DOI: 10.2147/IJGM.S349210] [Reference Citation Analysis]
51 Li B, Wei S, Yang L, Peng X, Ma Y, Wu B, Fan Q, Yang S, Li X, Jin H, Tang S, Huang M, Li H, Liu J. CISD2 Promotes Resistance to Sorafenib-Induced Ferroptosis by Regulating Autophagy in Hepatocellular Carcinoma. Front Oncol 2021;11:657723. [PMID: 34485112 DOI: 10.3389/fonc.2021.657723] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Yilmaz C, Karaca CA, Iakobadze Z, Farajov R, Kilic K, Doganay L, Kilic M. Factors Affecting Recurrence and Survival After Liver Transplantation for Hepatocellular Carcinoma. Transplant Proc. 2018;50:3571-3576. [PMID: 30577240 DOI: 10.1016/j.transproceed.2018.05.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
53 Byrne JD, Jajja MR, O'Neill AT, Bickford LR, Keeler AW, Hyder N, Wagner K, Deal A, Little RE, Moffitt RA, Stack C, Nelson M, Brooks CR, Lee W, Luft JC, Napier ME, Darr D, Anders CK, Stack R, Tepper JE, Wang AZ, Zamboni WC, Yeh JJ, DeSimone JM. Local iontophoretic administration of cytotoxic therapies to solid tumors. Sci Transl Med 2015;7:273ra14. [PMID: 25653220 DOI: 10.1126/scitranslmed.3009951] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 5.9] [Reference Citation Analysis]
54 Djokic M, Cemazar M, Bosnjak M, Dezman R, Badovinac D, Miklavcic D, Kos B, Stabuc M, Stabuc B, Jansa R, Popovic P, Smid LM, Sersa G, Trotovsek B. A Prospective Phase II Study Evaluating Intraoperative Electrochemotherapy of Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E3778. [PMID: 33333941 DOI: 10.3390/cancers12123778] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 He Y, Lu M, Che J, Chu Q, Zhang P, Chen Y. Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. Front Oncol 2021;11:716844. [PMID: 34552872 DOI: 10.3389/fonc.2021.716844] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Hosseinzadeh F, Verdi J, Ai J, Hajighasemlou S, Seyhoun I, Parvizpour F, Hosseinzadeh F, Iranikhah A, Shirian S. Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review. Cancer Cell Int 2018;18:133. [PMID: 30214375 DOI: 10.1186/s12935-018-0624-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
57 Field WBS, Rostas JW, Philps P, Scoggins CR, McMasters KM, Martin RCG 2nd. Wide versus narrow margins after partial hepatectomy for hepatocellular carcinoma: Balancing recurrence risk and liver function. Am J Surg 2017;214:273-7. [PMID: 28615138 DOI: 10.1016/j.amjsurg.2017.06.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
58 Mathewos M. Pathological and Cytological Studies on Hepatocellular Carcinoma in Cattle Slaughtered at Bishoftu Elfora Abattoir, Central Ethiopia. Vet Med Int 2021;2021:6649172. [PMID: 34035888 DOI: 10.1155/2021/6649172] [Reference Citation Analysis]
59 Herath NI, Devun F, Herbette A, Lienafa M, Chouteau P, Sun J, Dutreix M, Denys A. Potentiation of doxorubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models. Eur Radiol 2017;27:4435-44. [DOI: 10.1007/s00330-017-4792-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
60 Chen A, Li S, Yao Z, Hu J, Cao J, Topatana W, Juengpanich S, Yu H, Shen J, Chen M. Adjuvant transarterial chemoembolization to sorafenib in unresectable hepatocellular carcinoma: A meta-analysis. J Gastroenterol Hepatol 2021;36:302-10. [PMID: 32652685 DOI: 10.1111/jgh.15180] [Reference Citation Analysis]
61 Lu WL, Yang T, Song QJ, Fang ZQ, Pan ZQ, Liang C, Jia DW, Peng PK. Akebia trifoliata (Thunb.) Koidz Seed Extract inhibits human hepatocellular carcinoma cell migration and invasion in vitro. J Ethnopharmacol 2019;234:204-15. [PMID: 30528882 DOI: 10.1016/j.jep.2018.11.044] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
62 Chien M, Ho Y, Yang S, Yang Y, Lai S, Chen W, Chen M, Yeh C. Niclosamide, an oral antihelmintic drug, exhibits antimetastatic activity in hepatocellular carcinoma cells through downregulating twist-mediated CD10 expression. Environmental Toxicology 2018;33:659-69. [DOI: 10.1002/tox.22551] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
63 Shao YY, Hsu CH, Cheng AL. Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we? Liver Cancer 2013;2:93-107. [PMID: 24159601 DOI: 10.1159/000343845] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
64 Lei Q, Chen H, Zheng H, Deng F, Wang F, Li J, Hu J, Fu R, Zhen Z. Zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: A case report and literature review. Medicine (Baltimore) 2019;98:e14595. [PMID: 31045756 DOI: 10.1097/MD.0000000000014595] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
65 Hong L, Han Y, Zhang H, Zhao Q, Wu K, Fan D. Drug resistance-related miRNAs in hepatocellular cancer. Expert Rev Gastroenterol Hepatol 2014;8:283-8. [PMID: 24502538 DOI: 10.1586/17474124.2014.881713] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
66 Adjibade P, St-Sauveur VG, Quevillon Huberdeau M, Fournier MJ, Savard A, Coudert L, Khandjian EW, Mazroui R. Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells. Oncotarget 2015;6:43927-43. [PMID: 26556863 DOI: 10.18632/oncotarget.5980] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
67 Gomaa AI, Waked I. Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol 2015; 7(4): 673-687 [PMID: 25866604 DOI: 10.4254/wjh.v7.i4.673] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
68 Nai QY, Wei MX, Xu W. Regulatory mechanisms and therapeutic targeting of liver cancer stem cells. Shijie Huaren Xiaohua Zazhi 2016; 24(8): 1198-1205 [DOI: 10.11569/wcjd.v24.i8.1198] [Reference Citation Analysis]
69 Wang S, Deng Y, Yu X, Zhang XW, Huo CL, Sun ZG, Chang H. Prognostic significance of preoperative systemic inflammatory biomarkers in patients with hepatocellular carcinoma after microwave ablation and establishment of a nomogram. Sci Rep 2021;11:13814. [PMID: 34226605 DOI: 10.1038/s41598-021-93289-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
70 Luo Y, Wang P, Liu H, Zhu Z, Li C, Gao Y. The state of T cells before cryopreservation: Effects on post-thaw proliferation and function. Cryobiology 2017;79:65-70. [DOI: 10.1016/j.cryobiol.2017.08.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
71 Qi W, Zhang Q, Xu Y, Wang X, Yu F, Zhang Y, Zhao P, Guo H, Zhou C, Wang Z, Sun Y, Liu L, Xuan W, Wang J. Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy/ablation. J Viral Hepat 2020;27:387-96. [PMID: 31755220 DOI: 10.1111/jvh.13236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Ghinolfi D, Rreka E, Pezzati D, Filipponi F, De Simone P. Perfusion machines and hepatocellular carcinoma: a good match between a marginal organ and an advanced disease? Transl Gastroenterol Hepatol 2017;2:87. [PMID: 29264425 DOI: 10.21037/tgh.2017.10.01] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Abdelmoneem MA, Mahmoud M, Zaky A, Helmy MW, Sallam M, Fang JY, Elkhodairy KA, Elzoghby AO. Dual-targeted casein micelles as green nanomedicine for synergistic phytotherapy of hepatocellular carcinoma. J Control Release 2018;287:78-93. [PMID: 30138716 DOI: 10.1016/j.jconrel.2018.08.026] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 9.3] [Reference Citation Analysis]
74 Lai HH, Li CW, Hong CC, Sun HY, Chiu CF, Ou DL, Chen PS. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma. Mol Oncol 2019;13:928-45. [PMID: 30657254 DOI: 10.1002/1878-0261.12449] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
75 Xiang Y, Huang W, Huang C, Long J, Zhou Y, Liu Y, Tang S, He DX, Tan XW, Wei H, Yu CY. Facile Fabrication of Nanoparticles with Dual-Targeting Ligands for Precise Hepatocellular Carcinoma Therapy In Vitro and In Vivo. Mol Pharm 2020;17:3223-35. [PMID: 32658485 DOI: 10.1021/acs.molpharmaceut.0c00327] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
76 Fu XH, Li M, Lou HB, Huang MS, Liu CL. Investigating genetic characteristics of hepatitis B virus-associated and -non-associated hepatocellular carcinoma. Genet Res (Camb) 2016;98:e14. [PMID: 27834158 DOI: 10.1017/S0016672316000124] [Reference Citation Analysis]
77 Lin SM. Local ablation for hepatocellular carcinoma in taiwan. Liver Cancer 2013;2:73-83. [PMID: 24159599 DOI: 10.1159/000343843] [Cited by in Crossref: 26] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
78 Kim CW, Lee HJ, Jung JH, Kim YH, Jung DB, Sohn EJ, Lee JH, Woo HJ, Baek NI, Kim YC, Kim SH. Activation of Caspase-9/3 and Inhibition of Epithelial Mesenchymal Transition are Critically Involved in Antitumor Effect of Phytol in Hepatocellular Carcinoma Cells. Phytother Res 2015;29:1026-31. [PMID: 25892665 DOI: 10.1002/ptr.5342] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
79 Reichl P, Fang M, Starlinger P, Staufer K, Nenutil R, Muller P, Greplova K, Valik D, Dooley S, Brostjan C. Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma. Int J Cancer. 2015;137:385-394. [PMID: 25529751 DOI: 10.1002/ijc.29394] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
80 Carrillo FJ, Mattos AA, Vianey AF, Vezozzo DC, Marinho F, Souto FJ, Cotrim HP, Coelho HS, Silva I, Garcia JH. Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma. Arq Gastroenterol. 2015;52 Suppl 1:2-14. [PMID: 26959803 DOI: 10.1590/s0004-28032015000500001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
81 Dai Q, Yin Q, Wei L, Zhou Y, Qiao C, Guo Y, Wang X, Ma S, Lu N. Oroxylin A regulates glucose metabolism in response to hypoxic stress with the involvement of Hypoxia-inducible factor-1 in human hepatoma HepG2 cells: OROXYLIN A REGULATES GLUCOSE METABOLISM. Mol Carcinog 2016;55:1275-89. [DOI: 10.1002/mc.22369] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
82 Minami Y, Kudo M. Imaging Modalities for Assessment of Treatment Response to Nonsurgical Hepatocellular Carcinoma Therapy: Contrast-Enhanced US, CT, and MRI. Liver Cancer 2015;4:106-14. [PMID: 26697413 DOI: 10.1159/000367733] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
83 Deng Y, Zhang F, Sun ZG, Wang S. Development and Validation of a Prognostic Signature Associated With Tumor Microenvironment Based on Autophagy-Related lncRNA Analysis in Hepatocellular Carcinoma. Front Med (Lausanne) 2021;8:762570. [PMID: 34970559 DOI: 10.3389/fmed.2021.762570] [Reference Citation Analysis]
84 Fan A, Wei J, Yang M, Zhang Q, Zhang Y, Liu Q, Li N, Zhao D, Lu Y, Li J, Zhao J, Deng S, Zhang B, Zhu H, Chen X. Pharmacodynamic and pharmacokinetic characteristics of YMR-65, a tubulin inhibitor, in tumor-bearing mice. European Journal of Pharmaceutical Sciences 2018;121:74-84. [DOI: 10.1016/j.ejps.2018.05.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
85 Rios RS, Zheng KI, Zheng MH. Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. Chin Med J (Engl) 2021;134:2911-21. [PMID: 34855640 DOI: 10.1097/CM9.0000000000001888] [Reference Citation Analysis]
86 Hussein RS, Tantawy W, Abbas YA. MRI assessment of hepatocellular carcinoma after locoregional therapy. Insights Imaging 2019;10:8. [PMID: 30694398 DOI: 10.1186/s13244-019-0690-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
87 Hu DG, Mackenzie PI, Mckinnon RA, Meech R. Genetic polymorphisms of human UDP-glucuronosyltransferase (UGT) genes and cancer risk. Drug Metabolism Reviews 2016;48:47-69. [DOI: 10.3109/03602532.2015.1131292] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
88 Ou HY, Cheng YF, Chuang YH, Hsu HW, Chen CL, Lazo MZ, Weng CC, Yu CY, Tsang LL, Huang TL, Tong YS. Quantification of Functional MR Predicts Early Response in Post-doxorubicin Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma. Dig Dis Sci. 2019;. [PMID: 31732907 DOI: 10.1007/s10620-019-05951-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
89 Grillone A, Riva ER, Mondini A, Forte C, Calucci L, Innocenti C, de Julian Fernandez C, Cappello V, Gemmi M, Moscato S, Ronca F, Sacco R, Mattoli V, Ciofani G. Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles. Adv Healthc Mater 2015;4:1681-90. [PMID: 26039933 DOI: 10.1002/adhm.201500235] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 7.4] [Reference Citation Analysis]
90 Liberal J, Costa G, Carmo A, Vitorino R, Marques C, Domingues MR, Domingues P, Gonçalves AC, Alves R, Sarmento-ribeiro AB, Girão H, Cruz MT, Batista MT. Chemical characterization and cytotoxic potential of an ellagitannin-enriched fraction from Fragaria vesca leaves. Arabian Journal of Chemistry 2019;12:3652-66. [DOI: 10.1016/j.arabjc.2015.11.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
91 Chen G, Wei R, Huang X, Wang F, Chen Z. Synthesis and assessment of sodium alginate-modified silk fibroin microspheres as potential hepatic arterial embolization agent. International Journal of Biological Macromolecules 2020;155:1450-9. [DOI: 10.1016/j.ijbiomac.2019.11.122] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
92 Jędrzak A, Grześkowiak BF, Golba K, Coy E, Synoradzki K, Jurga S, Jesionowski T, Mrówczyński R. Magnetite Nanoparticles and Spheres for Chemo- and Photothermal Therapy of Hepatocellular Carcinoma in vitro. Int J Nanomedicine 2020;15:7923-36. [PMID: 33116509 DOI: 10.2147/IJN.S257142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
93 Lamerz R. Are Biomarkers Still Helpful in Hepatocellular Carcinoma? Digestion 2013;87:118-20. [DOI: 10.1159/000346282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
94 Comparetti EJ, Lins PMP, Quitiba J, Zucolotto V. Cancer cell membrane‐derived nanoparticles block the expression of immune checkpoint proteins on cancer cells and coordinate modulatory activity on immunosuppressive macrophages. J Biomedical Materials Res. [DOI: 10.1002/jbm.a.37387] [Reference Citation Analysis]
95 Lee WY, Bachtiar M, Choo CCS, Lee CG. Comprehensive review of Hepatitis B Virus-associated hepatocellular carcinoma research through text mining and big data analytics. Biol Rev Camb Philos Soc. 2019;94:353-367. [PMID: 30105774 DOI: 10.1111/brv.12457] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
96 Reynolds AR, Furlan A, Fetzer DT, Sasatomi E, Borhani AA, Heller MT, Tublin ME. Infiltrative Hepatocellular Carcinoma: What Radiologists Need to Know. RadioGraphics 2015;35:371-86. [DOI: 10.1148/rg.352140114] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 7.7] [Reference Citation Analysis]
97 Chang KF, Huang XF, Lin YL, Liao KW, Hsieh MC, Chang JT, Tsai NM. Positively Charged Nanoparticle Delivery of n-Butylidenephthalide Enhances Antitumor Effect in Hepatocellular Carcinoma. Biomed Res Int 2021;2021:8817875. [PMID: 33791383 DOI: 10.1155/2021/8817875] [Reference Citation Analysis]
98 Shi H, Huttad LV, Tan M, Liu H, Chua M, Cheng Z, So S. NIR-II imaging of hepatocellular carcinoma based on a humanized anti-GPC3 antibody. RSC Med Chem 2022;13:90-7. [DOI: 10.1039/d1md00313e] [Reference Citation Analysis]
99 Li W, Zhou X, Huang Z, Zhang H, Zhang L, Shang C, Chen Y. Laparoscopic surgery minimizes the release of circulating tumor cells compared to open surgery for hepatocellular carcinoma. Surg Endosc 2015;29:3146-53. [DOI: 10.1007/s00464-014-4041-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
100 Cardoso H, Alves AM, Marques M, Vale AM, Pereira P, Macedo G. Hepatocellular Carcinoma Treatment With Sorafenib: Real-Life Evaluation of Prognostic Factors and a Practical Clue for Patient Management. GE Port J Gastroenterol 2016;23:243-8. [PMID: 28868469 DOI: 10.1016/j.jpge.2016.04.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
101 Zhou X, Li R, Jing R, Zuo B, Zheng Q. Genome-wide CRISPR knockout screens identify ADAMTSL3 and PTEN genes as suppressors of HCC proliferation and metastasis, respectively. J Cancer Res Clin Oncol 2020;146:1509-21. [PMID: 32266537 DOI: 10.1007/s00432-020-03207-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
102 Xu G, Qi F, Zhang J, Xu J, Shi T, Miao Y. Overexpression of OCT4 contributes to progression of hepatocellular carcinoma. Tumour Biol 2016;37:4649-54. [PMID: 26508029 DOI: 10.1007/s13277-015-4285-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
103 Zhang X, Ng HLH, Lu A, Lin C, Zhou L, Lin G, Zhang Y, Yang Z, Zhang H. Drug delivery system targeting advanced hepatocellular carcinoma: Current and future. Nanomedicine. 2016;12:853-869. [PMID: 26772424 DOI: 10.1016/j.nano.2015.12.381] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 11.0] [Reference Citation Analysis]
104 Liu C, Zhou N, Li J, Kong J, Guan X, Wang X. Eg5 Overexpression Is Predictive of Poor Prognosis in Hepatocellular Carcinoma Patients. Dis Markers 2017;2017:2176460. [PMID: 28684886 DOI: 10.1155/2017/2176460] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
105 Mahmoud K, Swidan S, El-nabarawi M, Teaima M. Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01309-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Haag GM, Herrmann T, Jaeger D, Stremmel W, Schemmer P, Sauer P, Gotthardt DN. Outcomes and risk factors for cancer patients undergoing endoscopic intervention of malignant biliary obstruction. BMC Gastroenterol 2015;15:171. [PMID: 26637394 DOI: 10.1186/s12876-015-0399-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
107 Gu YF, Kong LT. Inhibiting p21-activated kinase (PAK7) enhances radiosensitivity in hepatocellular carcinoma. Hum Exp Toxicol 2021;:9603271211027948. [PMID: 34165002 DOI: 10.1177/09603271211027948] [Reference Citation Analysis]
108 Said A, Ghufran A. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma. World J Clin Oncol 2017; 8(6): 429-436 [PMID: 29291167 DOI: 10.5306/wjco.v8.i6.429] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 48] [Article Influence: 10.4] [Reference Citation Analysis]
109 Bartel K, Winzi M, Ulrich M, Koeberle A, Menche D, Werz O, Müller R, Guck J, Vollmar AM, von Schwarzenberg K. V-ATPase inhibition increases cancer cell stiffness and blocks membrane related Ras signaling - a new option for HCC therapy. Oncotarget 2017;8:9476-87. [PMID: 28036299 DOI: 10.18632/oncotarget.14339] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
110 Wu CH, Lee YH, Liang PC, Hu RH, Shih TT, Ho MC. Predictors of changes in preoperative tumor stage between dynamic computed tomography and gadoxetate disodium-enhanced magnetic resonance imaging for hepatocellular carcinoma. J Formos Med Assoc 2022:S0929-6646(21)00593-3. [PMID: 35033411 DOI: 10.1016/j.jfma.2021.12.026] [Reference Citation Analysis]
111 Thein HH, Khoo E, Campitelli MA, Zaheen A, Yi Q, De P, Earle CC. Trends in relative survival in patients with a diagnosis of hepatocellular carcinoma in Ontario: a population-based retrospective cohort study. CMAJ Open 2015;3:E208-16. [PMID: 26389099 DOI: 10.9778/cmajo.20140118] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
112 Brodeur CM, Thibault P, Durand M, Perreault JP, Bisaillon M. Dissecting the expression landscape of cytochromes P450 in hepatocellular carcinoma: towards novel molecular biomarkers. Genes Cancer 2019;10:97-108. [PMID: 31258835 DOI: 10.18632/genesandcancer.190] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
113 Rao Q, Li M, Xu W, Pang K, Guo X, Wang D, Liu J, Guo W, Zhang Z. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int 2020;14:765-75. [DOI: 10.1007/s12072-020-10064-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
114 Shi J, Keller JM, Zhang J, Keller ET. A review on the diagnosis and treatment of hepatocellular carcinoma with a focus on the role of Wnts and the dickkopf family of Wnt inhibitors. J Hepatocell Carcinoma 2014;1:1-7. [PMID: 27508171 DOI: 10.2147/JHC.S44537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
115 Chu YD, Lin KH, Huang YH, Lin CC, Hung CF, Yeh TS, Lee WC, Yeh CT. A novel thyroid function index associated with opposite therapeutic outcomes in advanced hepatocellular carcinoma patients receiving chemotherapy or sorafenib. Asia Pac J Clin Oncol 2018;14:e341-51. [PMID: 29785761 DOI: 10.1111/ajco.12983] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
116 Venkatraj N, Nanjan MJ, Loyer P, Chandrasekar MJN, Cammas Marion S. Poly(malic acid) bearing Doxorubicin and N-Acetyl Galactosamine as a site-specific prodrug for targeting hepatocellular carcinoma. J Biomater Sci Polym Ed 2017;28:1140-57. [PMID: 28357894 DOI: 10.1080/09205063.2017.1311294] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
117 Mou Y, Zhao Q, Zhong L, Chen F, Jiang T. Preliminary results of ultrasound-guided laser ablation for unresectable metastases to retroperitoneal and hepatic portal lymph nodes. World J Surg Oncol. 2016;14:165. [PMID: 27338093 DOI: 10.1186/s12957-016-0917-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
118 Tao R, Li X, Ran R, Xiao Z, Zhang H, Kong H, Song Q, Huang Y, Wang L, Huang J. A mixed analysis comparing nine minimally invasive surgeries for unresectable hepatocellular carcinoma patients. Oncotarget 2017;8:5460-73. [PMID: 27705924 DOI: 10.18632/oncotarget.12348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
119 Omar HA, Zaher DM, Srinivasulu V, Hersi F, Tarazi H, Al-Tel TH. Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma. Eur J Med Chem 2017;139:804-14. [PMID: 28865276 DOI: 10.1016/j.ejmech.2017.08.054] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
120 Shen S, Sun CY, Du XJ, Li HJ, Liu Y, Xia JX, Zhu YH, Wang J. Co-delivery of platinum drug and siNotch1 with micelleplex for enhanced hepatocellular carcinoma therapy. Biomaterials. 2015;70:71-83. [PMID: 26302232 DOI: 10.1016/j.biomaterials.2015.08.026] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
121 Luo J, Chen XQ, Li P. The Role of TGF-β and Its Receptors in Gastrointestinal Cancers. Transl Oncol 2019;12:475-84. [PMID: 30594036 DOI: 10.1016/j.tranon.2018.11.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 9.0] [Reference Citation Analysis]
122 Li J, Hou Y, Cai XB, Liu B. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. World J Gastroenterol 2016; 22(15): 4034-4040 [PMID: 27099447 DOI: 10.3748/wjg.v22.i15.4034] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
123 Dubé-Delarosbil C, St-Pierre Y. The emerging role of galectins in high-fatality cancers. Cell Mol Life Sci 2018;75:1215-26. [PMID: 29119229 DOI: 10.1007/s00018-017-2708-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
124 da Motta Girardi D, Correa TS, Crosara Teixeira M, Dos Santos Fernandes G. Hepatocellular Carcinoma: Review of Targeted and Immune Therapies. J Gastrointest Canc 2018;49:227-36. [DOI: 10.1007/s12029-018-0121-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
125 Bhardwaj N, Perera MT, Silva MA. Current Treatment Approaches to HCC with a Special Consideration to Transplantation. J Transplant 2016;2016:7926264. [PMID: 27413539 DOI: 10.1155/2016/7926264] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
126 Cheng K, Wang C, Chang Y, Hung T, Lai C, Kuo C, Huang H. Mulberry fruits extracts induce apoptosis and autophagy of liver cancer cell and prevent hepatocarcinogenesis in vivo. Journal of Food and Drug Analysis 2020;28:84-93. [DOI: 10.1016/j.jfda.2019.06.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
127 Porcu EP, Salis A, Rassu G, Maestri M, Galafassi J, Bruni G, Giunchedi P, Gavini E. Engineered polymeric microspheres obtained by multi-step method as potential systems for transarterial embolization and intraoperative imaging of HCC: Preliminary evaluation. European Journal of Pharmaceutics and Biopharmaceutics 2017;117:160-7. [DOI: 10.1016/j.ejpb.2017.04.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
128 Guo LN, Gao HY, He M, Liu D. Significance of expression of mannose receptor in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2016; 24(1): 37-43 [DOI: 10.11569/wcjd.v24.i1.37] [Reference Citation Analysis]
129 Hu C, Yang J, Huang Z, Liu C, Lin Y, Tong Y, Fan Z, Chen B, Wang C, Zhao CL. Diagnostic and prognostic nomograms for bone metastasis in hepatocellular carcinoma. BMC Cancer 2020;20:494. [PMID: 32487048 DOI: 10.1186/s12885-020-06995-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
130 Zhang D, Love T, Hao Y, Liu BL, Thung S, Fiel MI, Whitney-Miller CL, Liao X. Tumor Size, Not Small Vessel Invasion, Predicts Survival in Patients With Hepatocellular Carcinoma. Am J Clin Pathol 2022:aqac001. [PMID: 35142813 DOI: 10.1093/ajcp/aqac001] [Reference Citation Analysis]
131 Zaghloul RA, Elsherbiny NM, Kenawy HI, El-karef A, Eissa LA, El-shishtawy MM. Hepatoprotective effect of hesperidin in hepatocellular carcinoma: Involvement of Wnt signaling pathways. Life Sciences 2017;185:114-25. [DOI: 10.1016/j.lfs.2017.07.026] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
132 Periferakis A, Tsigas G, Periferakis AT, Badarau IA, Scheau AE, Tampa M, Georgescu SR, Didilescu AC, Scheau C, Caruntu C. Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma. Anal Cell Pathol (Amst) 2021;2021:1840069. [PMID: 34873567 DOI: 10.1155/2021/1840069] [Reference Citation Analysis]
133 Yu Y, Ai J, Zhang W. Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2017;11:925-37. [PMID: 28661190 DOI: 10.1080/17474124.2017.1343665] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
134 Xiangbao Y, Linquan W, Mingwen H, Fan Z, Kai W, Xin Y, Kaiyang W, Huaqun F. Humanized anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles, an antibody conjugate with potent and selective anti-hepatocellular carcinoma activity. Biomedicine & Pharmacotherapy 2014;68:597-602. [DOI: 10.1016/j.biopha.2014.04.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
135 Hui T, Chuah T, Low H, Tan C. Predicting early recurrence of hepatocellular carcinoma with texture analysis of preoperative MRI: a radiomics study. Clinical Radiology 2018;73:1056.e11-6. [DOI: 10.1016/j.crad.2018.07.109] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
136 Ehrlich SM, Liebl J, Ardelt MA, Lehr T, De Toni EN, Mayr D, Brandl L, Kirchner T, Zahler S, Gerbes AL, Vollmar AM. Targeting cyclin dependent kinase 5 in hepatocellular carcinoma – A novel therapeutic approach. Journal of Hepatology 2015;63:102-13. [DOI: 10.1016/j.jhep.2015.01.031] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
137 Koirala N, Das D, Fayazzadeh E, Sen S, McClain A, Puskas JE, Drazba JA, McLennan G. Folic acid conjugated polymeric drug delivery vehicle for targeted cancer detection in hepatocellular carcinoma. J Biomed Mater Res A 2019;107:2522-35. [PMID: 31334591 DOI: 10.1002/jbm.a.36758] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
138 Zhao R, Tin L, Zhang Y, Wu Y, Jin Y, Jin X, Zhang F, Li X. EF24 Suppresses Invasion and Migration of Hepatocellular Carcinoma Cells In Vitro via Inhibiting the Phosphorylation of Src. Biomed Res Int 2016;2016:8569684. [PMID: 27999817 DOI: 10.1155/2016/8569684] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
139 Hosseinzadeh F, Ai J, Ebrahimi-Barough S, Seyhoun I, Hajifathali A, Muhammadnejad S, Hosseinzadeh F, Shadnoush M, Dabiri Oskouei F, Verdi J. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2019;20:3797-803. [PMID: 31870124 DOI: 10.31557/APJCP.2019.20.12.3797] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
140 Chen X, Xia Z, Wan Y, Huang P. Identification of hub genes and candidate drugs in hepatocellular carcinoma by integrated bioinformatics analysis. Medicine (Baltimore) 2021;100:e27117. [PMID: 34596112 DOI: 10.1097/MD.0000000000027117] [Reference Citation Analysis]
141 Kim S, Choi S, Yoon JH, Kim Y, Lee S, Park T. Drug response prediction model using a hierarchical structural component modeling method. BMC Bioinformatics 2018;19:288. [PMID: 30367591 DOI: 10.1186/s12859-018-2270-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
142 Jia RR, Zhong JH, Huo RR, Su QB, Xiang X, Zhao FL, Qin ZB, Chen JH, Liao YY, Ma L, Xiang BD, Zhang CY, Li LQ. Correlation between serum prealbumin and prognosis of patients with hepatocellular carcinoma after hepatectomy. J Surg Oncol. 2019;119:794-800. [PMID: 30648280 DOI: 10.1002/jso.25378] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
143 El Dika I, Makki I, Abou-Alfa GK. Hepatocellular carcinoma, novel therapies on the horizon. Chin Clin Oncol 2021;10:12. [PMID: 32527116 DOI: 10.21037/cco-20-113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
144 Santini D, Pantano F, Riccardi F, Di Costanzo GG, Addeo R, Guida FM, Ceruso MS, Barni S, Bertocchi P, Marinelli S, Marchetti P, Russo A, Scartozzi M, Faloppi L, Santoni M, Cascinu S, Maiello E, Silvestris F, Tucci M, Ibrahim T, Masi G, Gnoni A, Comandone A, Fazio N, Conti A, Imarisio I, Pisconti S, Giommoni E, Cinieri S, Catalano V, Palmieri VO, Infante G, Aieta M, Trogu A, Gadaleta CD, Brunetti AE, Lorusso V, Silvestris N. Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey. PLoS One 2014;9:e105268. [PMID: 25170882 DOI: 10.1371/journal.pone.0105268] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
145 Kim HY, Park JW. Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future. Liver Cancer. 2014;3:9-17. [PMID: 24804173 DOI: 10.1159/000343854] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
146 Lu Z, Zuo B, Jing R, Gao X, Rao Q, Liu Z, Qi H, Guo H, Yin H. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. J Hepatol. 2017;67:739-748. [PMID: 28549917 DOI: 10.1016/j.jhep.2017.05.019] [Cited by in Crossref: 103] [Cited by in F6Publishing: 112] [Article Influence: 20.6] [Reference Citation Analysis]
147 Ramírez-Flores PN, Barraza-Reyna PJ, Aguirre-Vázquez A, Camacho-Moll ME, Guerrero-Beltrán CE, Resendez-Pérez D, González-Villasana V, Garza-González JN, Silva-Ramírez B, Castorena-Torres F, Bermúdez de León M. Isotretinoin and Thalidomide Down-Regulate c-MYC Gene Expression and Modify Proteins Associated with Cancer in Hepatic Cells. Molecules 2021;26:5742. [PMID: 34641286 DOI: 10.3390/molecules26195742] [Reference Citation Analysis]
148 Zhai Y, Ding D, Wei L, Chen E, Feng G. RETRACTED ARTICLE: Interference of Mucin 1 inhibits the growth of liver cancer cells by inducing mitochondria-mediated and death receptor-mediated cell apoptosis. Tumor Biol 2015;36:559-559. [DOI: 10.1007/s13277-014-2120-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
149 Berger NG, Tanious MN, Hammad AY, Miura JT, Mogal H, Clarke CN, Christians KK, Tsai S, Gamblin TC. External radiation or ablation for solitary hepatocellular carcinoma: A survival analysis of the SEER database. J Surg Oncol 2017;116:307-12. [PMID: 28464313 DOI: 10.1002/jso.24661] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
150 Wu Q, Chen X, Wang P, Wu Q, Qi X, Han X, Chen L, Meng X, Xu K. Delivery of Arsenic Trioxide by Multifunction Nanoparticles To Improve the Treatment of Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2020;12:8016-29. [PMID: 31997633 DOI: 10.1021/acsami.9b22802] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
151 Zhang J, Li H, Huang Z, He Y, Zhou X, Huang T, Dai P, Duan D, Ma X, Yin Q, Wang X, Liu H, Chen S, Zou F, Chen X. Hypoxia attenuates Hsp90 inhibitor 17-DMAG-induced cyclin B1 accumulation in hepatocellular carcinoma cells. Cell Stress Chaperones 2016;21:339-48. [PMID: 26786409 DOI: 10.1007/s12192-015-0664-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
152 Yan H, Jung KH, Kim J, Rumman M, Oh MS, Hong S. Artemisia capillaris extract AC68 induces apoptosis of hepatocellular carcinoma by blocking the PI3K/AKT pathway. Biomedicine & Pharmacotherapy 2018;98:134-41. [DOI: 10.1016/j.biopha.2017.12.043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
153 Liu J, Chen J, Liu H, Zhang K, Zeng Q, Yang S, Jiang Z, Zhang X, Chen T, Li D, Shan H. Bi/Se-Based Nanotherapeutics Sensitize CT Image-Guided Stereotactic Body Radiotherapy through Reprogramming the Microenvironment of Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2021;13:42473-85. [PMID: 34474563 DOI: 10.1021/acsami.1c11763] [Reference Citation Analysis]
154 Mauseth B, Camilio KA, Shi J, Hammarström CL, Rekdal Ø, Sveinbjørnsson B, Line PD. The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma. Mol Ther Oncolytics 2019;14:139-48. [PMID: 31211244 DOI: 10.1016/j.omto.2019.05.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
155 Rao Q, Zuo B, Lu Z, Gao X, You A, Wu C, Du Z, Yin H. Tumor-derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitro. Hepatology 2016;64:456-72. [PMID: 26990897 DOI: 10.1002/hep.28549] [Cited by in Crossref: 131] [Cited by in F6Publishing: 125] [Article Influence: 21.8] [Reference Citation Analysis]
156 Du S, Song X, Li Y, Cao Y, Chu F, Durojaye OA, Su Z, Shi X, Wang J, Cheng J, Wang T, Gao X, Chen Y, Zeng W, Wang F, Wang D, Liu X, Ding X. Celastrol inhibits ezrin-mediated migration of hepatocellular carcinoma cells. Sci Rep 2020;10:11273. [PMID: 32647287 DOI: 10.1038/s41598-020-68238-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
157 Minami Y, Kudo M. Therapeutic response assessment of transcatheter arterial chemoembolization for hepatocellular carcinoma: ultrasonography, CT and MR imaging. Oncology. 2013;84 Suppl 1:58-63. [PMID: 23428860 DOI: 10.1159/000345891] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
158 Luo D, Wang Z, Wu J, Jiang C, Wu J. The role of hypoxia inducible factor-1 in hepatocellular carcinoma. Biomed Res Int 2014;2014:409272. [PMID: 25101278 DOI: 10.1155/2014/409272] [Cited by in Crossref: 49] [Cited by in F6Publishing: 81] [Article Influence: 6.1] [Reference Citation Analysis]
159 Jeong KY, Lee EJ, Yang SH, Seong J. Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma. J Radiat Res 2015;56:37-45. [PMID: 25225286 DOI: 10.1093/jrr/rru077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
160 Rao Q, You A, Guo Z, Zuo B, Gao X, Zhang T, Du Z, Wu C, Yin H. Intrahepatic Tissue Implantation Represents a Favorable Approach for Establishing Orthotopic Transplantation Hepatocellular Carcinoma Mouse Models. PLoS One 2016;11:e0148263. [PMID: 26824903 DOI: 10.1371/journal.pone.0148263] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
161 Şirin N, Elmas L, Seçme M, Dodurga Y. Investigation of possible effects of apigenin, sorafenib and combined applications on apoptosis and cell cycle in hepatocellular cancer cells. Gene 2020;737:144428. [PMID: 32045658 DOI: 10.1016/j.gene.2020.144428] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
162 Liu Q, Liu J. Signaling pathways in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2014; 22(1): 59-66 [DOI: 10.11569/wcjd.v22.i1.59] [Reference Citation Analysis]
163 Chang M, Wu M, Li H. Antitumor activities of novel glycyrrhetinic acid-modified curcumin-loaded cationic liposomes in vitro and in H22 tumor-bearing mice. Drug Deliv 2018;25:1984-95. [PMID: 30499350 DOI: 10.1080/10717544.2018.1526227] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
164 Bhatia R, Ravulapati S, Befeler A, Dombrowski J, Gadani S, Poddar N. Hepatocellular Carcinoma with Bone Metastases: Incidence, Prognostic Significance, and Management-Single-Center Experience. J Gastrointest Cancer 2017;48:321-5. [PMID: 28891006 DOI: 10.1007/s12029-017-9998-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
165 Ingle PV, Samsudin SZ, Chan PQ, Ng MK, Heng LX, Yap SC, Chai AS, Wong AS. Development and novel therapeutics in hepatocellular carcinoma: a review. Ther Clin Risk Manag. 2016;12:445-455. [PMID: 27042086 DOI: 10.2147/tcrm.s92377] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
166 Zhang JN, Wei F, Lei LH, Yang Y, Yang Y, Zhou WP. Cyclin-Dependent Kinase 4 is expected to be a therapeutic target for hepatocellular carcinoma metastasis using integrated bioinformatic analysis. Bioengineered 2021. [PMID: 34784846 DOI: 10.1080/21655979.2021.2006942] [Reference Citation Analysis]
167 Zhang Z, Jiang H, Chen J, Wei Y, Cao L, Ye Z, Li X, Ma L, Song B. Hepatocellular carcinoma: radiomics nomogram on gadoxetic acid-enhanced MR imaging for early postoperative recurrence prediction.Cancer Imaging. 2019;19:22. [PMID: 31088553 DOI: 10.1186/s40644-019-0209-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 37] [Article Influence: 10.0] [Reference Citation Analysis]
168 Ding W, Yang H, Gong S, Shi W, Xiao J, Gu J, Wang Y, He B. Candidate miRNAs and pathogenesis investigation for hepatocellular carcinoma based on bioinformatics analysis. Oncol Lett 2017;13:3409-14. [PMID: 28521446 DOI: 10.3892/ol.2017.5913] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
169 Chiang MF, Tseng TK, Shih CW, Yang TH, Wu SY. Clinical and contrast-enhanced image features in the prediction model for the detection of small hepatocellular carcinomas. J Cancer 2020;11:7166-75. [PMID: 33193879 DOI: 10.7150/jca.47245] [Reference Citation Analysis]
170 Cevik D, Yildiz G, Ozturk M. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. World J Gastroenterol 2015; 21(1): 311-317 [PMID: 25574106 DOI: 10.3748/wjg.v21.i1.311] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
171 Tsai CL, Hsu FM, Cheng JC. How to Improve Therapeutic Ratio in Radiotherapy of HCC. Liver Cancer. 2016;5:210-220. [PMID: 27493896 DOI: 10.1159/000367767] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
172 Kahn J, Pregartner G, Schemmer P. Effects of both Pro- and Synbiotics in Liver Surgery and Transplantation with Special Focus on the Gut-Liver Axis-A Systematic Review and Meta-Analysis. Nutrients 2020;12:E2461. [PMID: 32824268 DOI: 10.3390/nu12082461] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
173 Zarębska I, Gzil A, Durślewicz J, Jaworski D, Antosik P, Ahmadi N, Smolińska-Świtała M, Grzanka D, Szylberg Ł. The clinical, prognostic and therapeutic significance of liver cancer stem cells and their markers. Clin Res Hepatol Gastroenterol 2021;45:101664. [PMID: 33667731 DOI: 10.1016/j.clinre.2021.101664] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Eman P, Chacon E, Gupta M, Berger JC, Shah MB, El Haddad HE, El-Husseini A, Dela Cruz AC, Grigorian A, Mei X, Gedaly R. Long term outcomes of patients transplanted for hepatocellular carcinoma with human immunodeficiency virus infection. HPB (Oxford) 2019;21:1009-16. [PMID: 30765199 DOI: 10.1016/j.hpb.2019.01.001] [Reference Citation Analysis]
175 Chiu CC, Lee KT, Wang JJ, Sun DP, Lee HH, Huang CC, Shi HY. Preoperative Health-Related Quality of Life Predicts Minimal Clinically Important Difference and Survival after Surgical Resection of Hepatocellular Carcinoma. J Clin Med 2019;8:E576. [PMID: 31035539 DOI: 10.3390/jcm8050576] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
176 Gani SA, Muhammad SA, Kura AU, Barahuie F, Hussein MZ, Fakurazi S. Effect of protocatechuic acid-layered double hydroxide nanoparticles on diethylnitrosamine/phenobarbital-induced hepatocellular carcinoma in mice. PLoS One 2019;14:e0217009. [PMID: 31141523 DOI: 10.1371/journal.pone.0217009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
177 Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M. Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer. 2015;4:253-262. [PMID: 26734579 DOI: 10.1159/000367743] [Cited by in Crossref: 73] [Cited by in F6Publishing: 81] [Article Influence: 10.4] [Reference Citation Analysis]
178 Monsignore LM, Elias-Junior J, Muglia VF, Teixeira AC, Mente ED, Martinelli Ade L, Abud DG. Addition of n-butyl cyanoacrylate to classic transarterial chemoembolization may improve the radiological response in patients with hepatocellular carcinoma. Clinics (Sao Paulo) 2015;70:781-9. [PMID: 26735217 DOI: 10.6061/clinics/2015(12)04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
179 Goodwin CR, Yanamadala V, Ruiz-Valls A, Abu-Bonsrah N, Shankar G, Sankey EW, Boone C, Clarke MJ, Bilsky M, Laufer I, Fisher C, Shin JH, Sciubba DM. A Systematic Review of Metastatic Hepatocellular Carcinoma to the Spine. World Neurosurg 2016;91:510-517.e4. [PMID: 27090971 DOI: 10.1016/j.wneu.2016.04.026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
180 Zhang X, El-Serag HB, Thrift AP. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare. Cancer Causes Control 2021;32:317-25. [PMID: 33394207 DOI: 10.1007/s10552-020-01386-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
181 Hu ZD, Jiang Y, Sun HM, Wang JW, Zhai LL, Yin ZQ, Yan J. KIF11 Promotes Proliferation of Hepatocellular Carcinoma among Patients with Liver Cancers. Biomed Res Int 2021;2021:2676745. [PMID: 33490265 DOI: 10.1155/2021/2676745] [Reference Citation Analysis]
182 Suemura S, Kodama T, Myojin Y, Yamada R, Shigekawa M, Hikita H, Sakamori R, Tatsumi T, Takehara T. CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1362. [PMID: 31540262 DOI: 10.3390/cancers11091362] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
183 Shi L, Feng Y, Lin H, Ma R, Cai X. Role of estrogen in hepatocellular carcinoma: is inflammation the key? J Transl Med. 2014;12:93. [PMID: 24708807 DOI: 10.1186/1479-5876-12-93] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 8.0] [Reference Citation Analysis]
184 Mei Z, Jiao H, Wang W, Li J, Chen G, Xu Y. Polycomb chromobox 4 enhances migration and pulmonary metastasis of hepatocellular carcinoma cell line MHCC97L. Sci China Life Sci 2014;57:610-7. [PMID: 24838576 DOI: 10.1007/s11427-014-4663-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
185 Buschauer S, Koch A, Wiggermann P, Müller M, Hellerbrand C. Hepatocellular carcinoma cells surviving doxorubicin treatment exhibit increased migratory potential and resistance to doxorubicin re-treatment in vitro. Oncol Lett 2018;15:4635-40. [PMID: 29541235 DOI: 10.3892/ol.2018.7887] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
186 Hu DG, Marri S, McKinnon RA, Mackenzie PI, Meech R. Deregulation of the Genes that Are Involved in Drug Absorption, Distribution, Metabolism, and Excretion in Hepatocellular Carcinoma. J Pharmacol Exp Ther 2019;368:363-81. [PMID: 30578287 DOI: 10.1124/jpet.118.255018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
187 Hubbard JM, Mahoney MR, Loui WS, Roberts LR, Smyrk TC, Gatalica Z, Borad M, Kumar S, Alberts SR. Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol. 2017;12:201-209. [PMID: 27943153 DOI: 10.1007/s11523-016-0467-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
188 Feng YX, Li W, Wen XD, Zhang N, Liu WH, Yang ZY. Sinusoidal Endothelial Cell Progenitor Cells Promote Tumour Progression in Patients with Hepatocellular Carcinoma. Stem Cells Int 2020;2020:8819523. [PMID: 33312206 DOI: 10.1155/2020/8819523] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
189 He X, Hikiba Y, Suzuki Y, Nakamori Y, Kanemaru Y, Sugimori M, Sato T, Nozaki A, Chuma M, Maeda S. EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells. Sci Rep 2022;12:8007. [PMID: 35568782 DOI: 10.1038/s41598-022-12076-w] [Reference Citation Analysis]
190 Chen J, Li X, Cheng Q, Ning D, Ma J, Zhang Z, Chen X, Jiang L. Retracted : Effects of cyclin D1 gene silencing on cell proliferation, cell cycle, and apoptosis of hepatocellular carcinoma cells. J Cell Biochem 2018;119:2368-80. [DOI: 10.1002/jcb.26400] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
191 Chen ZH, Feng JK, Sun JX, Wu JY, Guo WX, Shi J, Wei YG, Zhou JY, Zhang ZB, Yan ML, Cheng SQ. Postoperative adjuvant transarterial chemoembolization improves outcomes of hepatocellular carcinoma associated with bile duct tumor thrombus: a propensity score matching analysis. HPB (Oxford) 2021:S1365-182X(21)01625-7. [PMID: 34635434 DOI: 10.1016/j.hpb.2021.09.005] [Reference Citation Analysis]
192 Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, Lurje G. Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach. Int J Mol Sci 2019;20:E1465. [PMID: 30909504 DOI: 10.3390/ijms20061465] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
193 Gomes S, Bosco B, Loureiro JB, Ramos H, Raimundo L, Soares J, Nazareth N, Barcherini V, Domingues L, Oliveira C, Bisio A, Piazza S, Bauer MR, Brás JP, Almeida MI, Gomes C, Reis F, Fersht AR, Inga A, Santos MMM, Saraiva L. SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1151. [PMID: 31405179 DOI: 10.3390/cancers11081151] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]